A big thanks to our
Founding Corporate Partners
BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20+ year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. Visit our website to learn more.
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity. You can learn more about the business of Kyowa Kirin on our website.
*Harmony and loop among people.
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We are driven by a true understanding of the critical nature of our mission, we harness the power of science and meaningful relationships to create new possibilities for patients who need them. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options, and that as such, there is no room for passengers. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We have two rare disease product candidates, one for the treatment of osteogenesis imperfecta (OI) and one primarily for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, Mereo has two oncology product candidates in clinical development.